Redwood Pharma Investor Relations Material
Latest events
Q1 2024
23 Apr, 2024
Q4 2023
15 Feb, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Redwood Pharma
Access all reports
Redwood Pharma AB focuses on developing innovative ophthalmic therapies, particularly for dry eye disease (DED). Utilizing its patented IntelliGel technology, the company aims to enhance drug delivery, allowing for reduced dosages and decreased dosing frequency, thus minimizing potential systemic toxicities. Redwood Pharma's strategy involves early-stage clinical development with the intent to license its products to larger pharmaceutical firms for global distribution. Redwood Pharma is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq Stockholm.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
REDW
Country
🇸🇪 Sweden